Crikzo-250 Crizotinib Capsules

Name: Crikzo-250 Crizotinib Capsules
Brand: PATHGENE PHARMA DISTRIBUTORS
Price: 6300 INR
Availability: InStock

Price 6300 INR/ Box

Get a Price/Quote

MOQ : 50 Boxes

Crikzo-250 Crizotinib Capsules Specification

Indication
Used in the treatment of non-small cell lung cancer (NSCLC)

Dosage Form
Capsules

Salt Composition
Crizotinib 250 mg

Feature
Targeted therapy for ALK-positive and ROS1-positive NSCLC

Ingredients
Crizotinib and excipients

Application
Oral administration for cancer therapy

Physical Color/Texture
Solid, capsule form

Storage Instructions
Store below 30C, protect from moisture

Shelf Life
24 months from the date of manufacture

Therapeutic Class
Antineoplastic (anticancer drug)

Packaging Size
30 capsules per box

Warning
To be sold by retail on the prescription of an oncologist only

Marketed By
Brand - Crikzo

Prescription
Required

Administration Route
Oral

Strength
250 mg per capsule

Crikzo-250 Crizotinib Capsules Trade Information

Minimum Order Quantity
50 Boxes

Payment Terms
Cash in Advance (CID)

Supply Ability
1000 Boxes Per Month

Delivery Time
2-5 Days

Main Domestic Market
All India

About Crikzo-250 Crizotinib Capsules

Elevate your cancer treatment regimen with Crikzo-250 Crizotinib Capsules, the premier anticancer solution designed for astonishing efficacy. Each splendiferous box contains 30 capsules, delivering a robust 250 mg of Crizotinib per capsule, specially formulated for ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). With instant savings and a special rate available, simply add to cart and enjoy the peace of mind of precise, targeted oral therapy. Only available via prescription from your oncologist, Crikzo-250 ensures optimal results while prioritizing your safety and well-being.

Targeted Oral Therapy for NSCLC

Crikzo-250 Crizotinib Capsules are specifically indicated for ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). This targeted therapy harnesses the effectiveness of Crizotinib, working actively against cancer cell proliferation. Designed for oral administration, Crikzo-250 offers patients a convenient usage type with premier performance and remarkable clinical results. Tailored for individuals seeking advanced oncological intervention, it ensures reliable and precise dosage in solid capsule form for maximal therapeutic advantage.

Domestic Market Coverage & Seamless Transaction Experience

Crikzo-250 is widely available across the main domestic market of India, handover to trusted suppliers and traders ensuring prompt fulfillment. The list price is transparently displayed, with secured payment terms including advance and online banking options. Once your order is placed, expect capsules to be shipped efficiently to your location. Each batch comes with necessary certifications, confirming quality and compliance for every customer. Experience a streamlined process from purchase to delivery.

FAQ's of Crikzo-250 Crizotinib Capsules:

Q: How should Crikzo-250 Crizotinib Capsules be stored to maintain potency?

A: Store Crikzo-250 Crizotinib Capsules below 30C, protected from moisture, and keep the packaging sealed until use to preserve their efficacy.

Q: What is the primary therapeutic application of Crikzo-250 Crizotinib?

A: Crikzo-250 is chiefly used for treating patients diagnosed with ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC), offering targeted anticancer action.

Q: When should a patient start using Crikzo-250 Capsules?

A: Usage of Crikzo-250 should commence only after receiving a prescription from an oncologist, as part of a tailored cancer treatment plan.

Q: Where can Crikzo-250 Crizotinib Capsules be purchased?

A: These capsules are available through authorized suppliers and traders in India and must be sold by retail strictly on prescription from specialized oncologists.

Q: What are the benefits of targeted therapy with Crikzo-250?

A: Targeted therapy with Crikzo-250 provides potent, focused treatment against specific cancer types, minimizing harm to healthy cells and enhancing treatment outcomes.